Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.
暂无分享,去创建一个
Claude Preudhomme | Daniel Birnbaum | Olivier Kosmider | Nicholas C P Cross | Michael A Morgan | D. Birnbaum | O. Bernard | C. Preudhomme | N. Cross | S. de Botton | M. Morgan | V. Della Valle | N. Vey | M. Fontenay | Aline Renneville | O. Kosmider | V. Gelsi-Boyer | O. Beyne-Rauzy | F. Dreyfus | L. Couronné | C. Hidalgo-Curtis | L. Scourzic | N. Carbuccia | T. Prebet | F. Damm | Aline Renneville | Frederik Damm | Véronique Gelsi-Boyer | Nadine Carbuccia | Claire Hidalgo-Curtis | Véronique Della Valle | Lucile Couronné | Laurianne Scourzic | Virginie Chesnais | Agnes Guerci-Bresler | Bohrane Slama | Odile Beyne-Rauzy | Aline Schmidt-Tanguy | Aspasia Stamatoullas-Bastard | François Dreyfus | Thomas Prébet | Stéphane de Botton | Norbert Vey | Olivier A Bernard | Michaela Fontenay | A. Guerci-Bresler | B. Slama | A. Schmidt-Tanguy | V. Chesnais | A. Stamatoullas-Bastard | Claire E Hidalgo-Curtis
[1] Daniel Birnbaum,et al. Mutations of polycomb‐associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia , 2009, British journal of haematology.
[2] C. Bloomfield,et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.
[3] O. Abdel-Wahab,et al. The most commonly reported variant in ASXL1 (c.1934dupG;p.Gly646TrpfsX12) is not a somatic alteration , 2010, Leukemia.
[4] Li Ding,et al. RECURRENT MUTATIONS IN THE U2AF1 SPLICING FACTOR IN MYELODYSPLASTIC SYNDROMES , 2011, Nature Genetics.
[5] R. Levine,et al. Mutation in TET2 in myeloid cancers. , 2009, The New England journal of medicine.
[6] A. Hagemeijer,et al. Acquired mutations in TET2 are common in myelodysplastic syndromes , 2009, Nature Genetics.
[7] J. Licht,et al. DNMT3A mutations in acute myeloid leukemia , 2011, Nature Genetics.
[8] C. Will,et al. The Spliceosome: Design Principles of a Dynamic RNP Machine , 2009, Cell.
[9] M. Stratton,et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. , 2011, The New England journal of medicine.
[10] B. Ko,et al. Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations. , 2010, Blood.
[11] O. Abdel-Wahab,et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. , 2011, Cancer cell.
[12] D. Birnbaum,et al. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). , 2009, Blood.
[13] Frequent Pathway Mutations of Splicing Machinery in Myelodysplasia , 2011 .
[14] D. Birnbaum,et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms , 2010, Leukemia.
[15] P. Opolon,et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. , 2011, Cancer cell.
[16] R. Kuiper,et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes , 2010, Nature Genetics.
[17] R. Arceci,et al. Incidence and Prognostic Influence of DNMT3A Mutations in Acute Myeloid Leukemia , 2011 .
[18] E. Korn. Censoring distributions as a measure of follow-up in survival analysis. , 1986, Statistics in medicine.
[19] M. Heuser,et al. SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications , 2012, Leukemia.
[20] D. Birnbaum,et al. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia , 2010, British journal of haematology.
[21] Feng-Chun Yang,et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. , 2011, Blood.
[22] D.,et al. Regression Models and Life-Tables , 2022 .
[23] Bob Löwenberg,et al. Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value , 2012, Haematologica.
[24] K. Döhner,et al. Prognostic implications and molecular associations of NADH dehydrogenase subunit 4 (ND4) mutations in acute myeloid leukemia , 2012, Leukemia.
[25] A. Jankowska,et al. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts , 2012, Leukemia.
[26] Peter J Campbell,et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms , 2011, Blood.
[27] F. Sigaux,et al. Myelodysplasia and leukemia of Fanconi anemia are associated with a specific pattern of genomic abnormalities that includes cryptic RUNX1/AML1 lesions. , 2011, Blood.
[28] C. Schumann,et al. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] H. Drexler,et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders , 2010, Nature Genetics.
[30] S. Ogawa,et al. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms , 2009, Nature.
[31] Michael Heuser,et al. IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis , 2010, Haematologica.
[32] G. Garcia-Manero,et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. , 2012, Blood.
[33] D. Neuberg,et al. Clinical effect of point mutations in myelodysplastic syndromes. , 2011, The New England journal of medicine.
[34] Stefan N Constantinescu,et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. , 2005, Nature.
[35] Li Ding,et al. Recurrent DNMT3A Mutations in Patients with Myelodysplastic Syndromes , 2011, Leukemia.
[36] S. Daignault,et al. TET2 and DNMT3A Mutations in Human T-Cell Lymphoma , 2012 .
[37] M. Jädersten,et al. Myelodysplastic syndromes: biology and treatment , 2009, Journal of internal medicine.